Characterization of ADC by LC/MS/MS

Antibody drug conjugates (ADCs) has become promising therapy for the treatment of cancers. Among all the ADCs
under developing, 2/3 of them are interchain cysteine linked ADCs. The ADCs are manufactured by partially reduce
the 4 pairs of interchain disulfide bond followed by conjugate cytotoxic payloads to the thiols, as a consequence, the
antibodies are linked with 0, 2, 4, 6, 8 drugs. The drug to antibody ratio (DAR) and the drug linking position are
important parameters that affect the therapeutic effects and need to be well characterized.

Thank you for registering!

You now have the option of downloading the resource or viewing the web version below.